Does Medicaid cover Zepbound?
Two answers, and your diagnosis picks between them. For moderate to severe sleep apnea every state has to cover Zepbound. For weight it is up to the state — and among the few that cover a GLP-1 for obesity at all, not every one puts Zepbound on the list.
Does Medicaid cover Zepbound?
Yes for moderate to severe obstructive sleep apnea in adults with obesity: that use is not weight loss, so a state cannot exclude it and can only manage it with prior authorization. For weight it depends on the state, and on whether the state's list names Zepbound — the documents quoted below say which. 11 of 51 state programs cover a GLP-1 for obesity at all, and the documents of 9 of them mention Zepbound by name — set out below, because mentioning is not always covering.
Sleep apnea: the use no state can exclude
The Social Security Act lets a Medicaid program exclude “agents when used for anorexia, weight loss, or weight gain”. That is an option about a use, not a molecule. Zepbound's second indication, moderate to severe obstructive sleep apnea in adults with obesity, is not weight loss, so a state that covers no drug for obesity still covers Zepbound for sleep apnea. What it may do is require prior authorization and write the criteria.
The request has to say sleep apnea and carry the sleep study. Filed under weight in a state that excludes weight loss, it is refused at the first step whatever else is in the chart; filed under sleep apnea, it is judged on that indication's own criteria.
Read from FDA prescribing information for ZEPBOUND, via DailyMed and Social Security Act §1927(d)(2).
What each state's document says about Zepbound
What this site recorded for 12 of the 51 programs names Zepbound. Each line is from what this site recorded for that state, read from the document linked under it — covering states first.
DelawareCovered, with prior authorization for obesity
- Two preferred products first — Wegovy, Wegovy HD, Zepbound, Contrave and phentermine are the preferred ones; Saxenda, Foundayo, Xenical and the oral Wegovy are not.
- The PDL, now effective 7 September 2026, is what makes Wegovy, Wegovy HD, Zepbound, Contrave and phentermine preferred and requires two preferred products before any non-preferred one; every agent in the class needs prior authorization either way.
Delaware DMAP prior authorization request: GLP-1 agonist for weight management, MASH or prevention of MACE, dated 2026-04-20; read 2026-09-05.
KansasCovered, with prior authorization for obesity
- The one number the form prints, a BMI of 40 or more (at 12–17, 40 or 140% of the 95th percentile), applies only to the 'high cost' agents in Table 4 of the clinical criteria — and the form states that Zepbound has not been in that table since 1 April 2024, nor Wegovy since 1 June 2025.
- Saxenda, Wegovy and Zepbound each need prior authorization; a non-preferred choice needs written clinical rationale, and the treatment plan has to include diet and physical activity.
KDHE Anti-Obesity Medications Prior Authorization Form, dated 2025-06-01; read 2026-09-05.
MinnesotaCovered, with prior authorization for obesity
- The covered list runs Saxenda, Wegovy, Zepbound, Contrave, Xenical, orlistat and the phentermine class.
Minnesota Health Care Programs PA criteria: Anti-Obesity Medications, dated 2026-08-01; read 2026-09-05.
MississippiCovered, with prior authorization for obesity
- Zepbound is not covered for weight loss.
Anti-obesity Select Agents PA Criteria, dated 2024-03-12; read 2026-09-05.
MissouriCovered, with prior authorization for obesity
- Zepbound is the preferred obesity agent.
- Mounjaro needs a written medical reason why Zepbound cannot be used.
- Anyone already on Zepbound before MO HealthNet covered it has to produce the BMI at the start of therapy, the current BMI, how they were paying and the three most recent fill dates.
MO HealthNet GLP-1 Receptor Agonists for All Indications prior authorization form, dated 2024-10-01; read 2026-09-10.
North CarolinaCovered, with prior authorization for obesity
- Wegovy and Saxenda 12+, Zepbound 18+
NC Medicaid Outpatient Pharmacy Prior Approval Criteria — GLP-1s for Weight Management, dated 2024-08-01; read 2026-09-05.
Rhode IslandCovered, with prior authorization for obesity
- Wegovy is the only preferred agent; Zepbound, Saxenda, oral Wegovy, Xenical, orlistat, phentermine/topiramate and Imcivree are non-preferred
Rhode Island Medicaid Fee for Service Preferred Drug List, dated 2026-01-13; read 2026-09-05.
TennesseeCovered, with prior authorization for obesity
- Wegovy and Saxenda start at 12, Zepbound at 18.
- Wegovy and Zepbound are preferred and need prior authorization.
Clinical Criteria, Step Therapy, and Quantity Limits for the TennCare PDL, dated 2026-09-01; read 2026-09-05.
VirginiaCovered, with prior authorization for obesity
- Wegovy and Saxenda 12+, Zepbound, Wegovy HD and Foundayo 18+
Virginia Medicaid Service Authorization — Weight Loss Management, dated 2026-07-01; read 2026-09-05.
CaliforniaNot covered for obesity
- Wegovy, Zepbound and Saxenda approvals ended on 31 December 2025 and there is no continuing care.
- Wegovy stays covered for MASH and, with prior authorization, for cardiovascular disease; Zepbound for obstructive sleep apnea; the diabetes GLP-1s on a diabetes diagnosis code.
Medi-Cal Rx: Changes to GLP-1 Drug Coverage, effective 1 January 2026, dated 2026-01-01; read 2026-08-20.
New MexicoA weight-loss drug, but no GLP-1 for obesity
- Fee-for-service covers phentermine, orlistat, benzphetamine and phendimetrazine among others, with prior authorization at a BMI over 40, or over 35 with hypertension, diabetes or dyslipidemia, for three months at a time; Wegovy, Zepbound and Saxenda are listed by name as not covered.
New Mexico Health Care Authority: Weight Reduction Medications, dated 2025-03-04; read 2026-09-10.
UtahNot covered for obesity
- For the indications Utah still covers: Wegovy for a prior major adverse cardiovascular event needs a BMI of 27 or more with a documented MI, stroke or symptomatic peripheral arterial disease and guideline-directed secondary prevention; Zepbound for sleep apnea needs a BMI of 30 or more, an apnea-hypopnea index of 15 or higher on an attended study, a sleep specialist and 70% adherence to PAP; Wegovy for MASH needs stage F2 to F3 fibrosis confirmed two ways and a liver specialist.
- On the other indications: Wegovy for cardiovascular risk renews for 12 months on 5% weight loss held from week 20; Zepbound for sleep apnea on a 20% fall in the apnea-hypopnea index; Wegovy for MASH on documented clinical response.
Utah Medicaid pharmacy prior authorization request form: GLP-1 medications for weight-related comorbidities, last updated 1 June 2026 (read via the Internet Archive), dated 2026-06-01; read 2026-09-05.
Also covering a GLP-1 for obesity, with nothing recorded here that names Zepbound: Michigan, Wisconsin. Zepbound appears nowhere in Wisconsin's anti-obesity prior-authorization attachment. Their preferred-drug lists decide which products are on it.
The card, and the cash price
The maker's savings card is not an option on Medicaid. Every manufacturer excludes government beneficiaries, because federal anti-kickback rules bar a maker from subsidizing a federal program's copay. If your state says no and you pay cash, Zepbound is $449 a month once titrated, read from its own published page on 2026-08-19.
If Medicaid says no
Federal Medicaid law requires an answer to a drug prior authorization within 24 hours, and a 72-hour emergency supply while it is pending. In a managed care plan you have 60 days from a denial to appeal to the plan, which must decide within 30 days, or 72 hours if it is urgent. On a decision the state makes itself, it may allow up to 90 days to ask for a fair hearing. Social Security Act §1927(d)(5); 42 CFR 438.402; 42 CFR 438.408; 42 CFR 431.221
What a Zepbound request has to show → The appeal letter builder fills in your state's own criteria and the fair-hearing rules.
Medicaid and Zepbound, answered
- Does Medicaid cover Zepbound for sleep apnea?
- Yes. Moderate to severe obstructive sleep apnea in adults with obesity is an FDA-approved use that is not weight loss, and the statute lets states exclude only weight loss. Expect prior authorization asking for the sleep study.
- Does Medicaid cover Zepbound for weight loss?
- Only in states that cover a GLP-1 for obesity and include Zepbound on their list. Some covering states prefer Wegovy and treat Zepbound as non-preferred or leave it out altogether; the state documents on this page say which.
- Can I use the Zepbound savings card with Medicaid?
- No. Lilly's terms exclude anyone in a state or federal program, and federal anti-kickback rules are why every maker writes them that way.